Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.81 -1.89 (-1.26%)
Streaming Delayed Price Updated: 2:01 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
From Johnson & Johnson
Via Business Wire
Verizon, Walgreens, 3M: 3 high-yield Dow stocks to buy now?
Dow's high-yielding trio, Verizon, Walgreens, and 3M face challenges, which are reflected in their stock-price declines. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Johnson & Johnson
Via Business Wire
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Exposures COVID-19
Intuitive Surgical’s post-earnings dip is a healthy time to buy
Intuitive Surgical had a solid quarter, but strength was expected, and the stock sold off; a healthy correction is good, but will investors buy the dip? 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 personal care stocks that smell like good earnings plays
Management remarks about how they plan to use technology to drive growth could matter just as much as near-term financials for these personal care companies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
From Johnson & Johnson
Via Business Wire
3 undervalued stocks: Is now the right time to buy?
WK Kellogg, Newmont, and WEC Energy Group have upside potential as undervalued stocks, although each is navigating challenges that pushed valuations lower. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
From Johnson & Johnson
Via Business Wire
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
From Johnson & Johnson
Via Business Wire
Asana sold the rip. Is it time to buy the dip?
Asana stock plunged as investors sold the news on its bullish earnings report, but with the company raising guidance, it may be time for investors buy the dip - 
Via MarketBeat
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
From Johnson & Johnson
Via Business Wire
Financial Resources Federal Credit Union Goes Live With Scienaptic's AI Platform
Increased automation will continue to support Credit Union's Growth and MissionNEW YORK - Dec. 6, 2023 - PRLog -- Leading global AI-powered credit decision platform provider, Scienaptic AI, announced... 
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Johnson & Johnson MedTech Acquires Laminar, Inc.
From Johnson & Johnson MedTech
Via Business Wire
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
2023's most anticipated IPOs weren't always the big winners
146 U.S. companies went public in 2023, down 16.09% from last year. Despite market ups and downs, the Renaissance index of IPOs is outperforming the S&P 500 
Via MarketBeat
Topics ETFs Initial Public Offering Stocks
Exposures Securities Market US Equities
Daily Wear Contact Lenses Market May See a Big Move: Major Giants Alcon, Hydron, Lagado Corporation, Metro Optics, Johnson & Johnson Vision Care
According to HTF Market Intelligence, the Global Daily Wear Contact Lenses Market Breakdown by Application (Corrective Lenses, Therapeutic Lenses, Cosmetic Lenses, Lifestyle-Oriented Lenses) by Type... 
Via SBWire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by... 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.